Literature DB >> 10415005

Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens.

M Pérez-Melgosa1, D Hollenbaugh, C B Wilson.   

Abstract

CD40 ligand (CD40L) plays a crucial role in T cell-dependent B cell responses, but whether its abundance is a limiting factor in their development is unclear. This question was addressed in transgenic mice expressing the murine CD40L gene under the control of the IL-2-promoter (CD40Ltg+). The fraction of activated T cells from the CD40Ltg+ mice with detectable levels of surface CD40L was modestly greater (1.1- to 2-fold) than littermate controls and paralleled an approximately 1.8-fold increase in CD40L mRNA abundance. In response to trinitrophenol (TNP)-keyhole limpet hemocyanin and tetanus/diphtheria vaccine, CD40Ltg+ mice developed higher titers of high-affinity IgG and IgG1 Ab than wild-type mice. In contrast, the Ab response of CD40Ltg+ and control mice was similar in response to the T-independent Ag TNP-Ficoll. These results suggest that a modest increment in expression of CD40L accelerates the development of T-dependent responses, and that CD40L plays a limiting role in the induction of high-affinity Ab and Ab-class switching.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415005

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Fortifying B cells with CD154: an engaging tale of many hues.

Authors:  J Gordon; J D Pound
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

Review 2.  Targeting CD40L: a promising therapeutic approach.

Authors:  Dimitris Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

3.  Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients.

Authors:  Cécile Contin; Vincent Pitard; Yahsou Delmas; Nadège Pelletier; Thierry Defrance; Jean-François Moreau; Pierre Merville; Julie Déchanet-Merville
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

4.  Effects of environmentally-relevant levels of perfluorooctane sulfonate on clinical parameters and immunological functions in B6C3F1 mice.

Authors:  Patricia A Fair; Erin Driscoll; Meagan A M Mollenhauer; Sarah G Bradshaw; Se Hun Yun; Kurunthachalam Kannan; Gregory D Bossart; Deborah E Keil; Margie M Peden-Adams
Journal:  J Immunotoxicol       Date:  2011-01-24       Impact factor: 3.000

Review 5.  When the balance is broken: X-linked gene dosage from two X chromosomes and female-biased autoimmunity.

Authors:  Camille M Syrett; Montserrat C Anguera
Journal:  J Leukoc Biol       Date:  2019-05-24       Impact factor: 4.962

6.  HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia.

Authors:  J Wang; W Zhang; M A Nardi; Z Li
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

Review 7.  CD154 transcriptional regulation in primary human CD4 T cells.

Authors:  Randy Q Cron
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

8.  Mechanism of reduced T-cell effector functions and class-switched antibody responses to herpes simplex virus type 2 in the absence of B7 costimulation.

Authors:  Lydia G Thebeau; Lynda A Morrison
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  In vitro and in vivo immunosuppressive activity of a novel anthracycline, 13-deoxy, 5-iminodoxorubicin.

Authors:  Richard D Olson; Mark B Headley; Alma Hodzic; Gerald M Walsh; Denise G Wingett
Journal:  Int Immunopharmacol       Date:  2007-02-14       Impact factor: 4.932

10.  The dinucleotide repeat polymorphism in the 3'UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus.

Authors:  M J Citores; I Rua-Figueroa; C Rodriguez-Gallego; A Durántez; M I García-Laorden; C Rodríguez-Lozano; J C Rodríguez-Pérez; J A Vargas; P Pérez-Aciego
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.